Medical Advocates

HCV Infection/Disease

 
Drugs

General Reports
HCV Protease Inhibitors

Amantadine
Atazanavir

Daclatasvir
Dasabuvir
Erythropoietin

Interferons
Ledipasvir


Mericitabine
Nevirapine
Ombitasvir
Paritaprevir
Peg Interferon-Alfa-2a 
Peg Interferon-Alfa-2b  
Raltegravir
Ribavirin
Rifampin



Rituximab
Sofosbuvir
Statins
Steroid Therapy
Tacrolimus
Alternative Therapies
Investigational Therapies
Post-Transplant Drugs
Viekira Pak/Holkira

HCV Main Page Main New/Newsworthy    Home Page    

Last Update:  September 01, 2015
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
FULL-TEXT ARTICLE

Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.
Woodrell C, Weiss J, Branch A, et al
J Addict Med. 2015 Aug 17.
Abstract

Direct-acting antiviral drugs for the treatment of chronic hepatitis c virus infection: Interferon free is now.
Florian J, Mishra P, Arya V, et al
Clin Pharmacol Th
er
. 2015 Jul 14.
Abstract

Hepatitis C Virus Drug Resistance-associated Substitutions: State of the Art Summary.
Lontok E, Harrington P, Howe A, et al
Hepatology. 2015 Jun 10
.
Abstract

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
Gutierrez JA, Lawitz EJ, Poordad F.
J Viral Hepat
. 2015 Jun 17. .
Abstract

Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma.
Hsu YC, Wu CY, Lin JT.
Semin Oncol
. 2015 Apr;42(2):329-338.
Abstract

Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus.
Najafzadeh M, Andersson K, Shrank , et al
Ann Intern Med
. 2015 Mar 17
.
Abstract

A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
Burgess S, Partovi N, Yoshida EM, et al
Ann Pharmacother
. 2015 Mar 13..
Abstract

Revolution in hepatitis C antiviral therapy.
Sadler MD, Lee SS.
Br Med Bull. 2015 Feb 13.
Abstract

The changing face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A.
Rai D, Wang L, Jiang X, et al
Curr Med Chem. 2015 Feb 9.
Abstract

Hepatitis C therapy: Looking toward interferon-sparing regimens.
Au TH, Destache CJ, Vivekanandan R.
J Am Pharm Assoc
(2003)
. 2015 Feb 6:e72-e8
Paper

Prescription of new HCV-drugs - what has to be considered judicially.
Mauss S.
Z Gastroenterol
. 2015 Jan;53(1):43-5.

Abstract

Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.
Cortez KJ, Kottilil S.
Ther Adv Chronic Dis. 2015 Jan;6(1):4-14.
Abstract

Drug interactions with new hepatitis C oral drugs.
Soriano V, Labarga P, Barreiro P, et al
Expert Opin Drug Metab Toxicol
. 2015 Jan 2:1-9.
Abstract

Current and future HCV therapy: do we still need other anti-HCV drugs?
Petta S, Craxì A.

Liver Int
. 2015 Jan;35 Suppl s1:4-10.

Abstract

Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
Sarrazin C, Wedemeyer H, Cloherty G,  et al
J Virol Methods
. 2014 Dec 18. pii: S0166-0934(14)00474-1
Abstract

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
Applegate TL, Gaudieri S, Plauzolles A,  et al
Antivir Ther
. 2014 Aug 8.
Abstract

Antiviral treatment of hepatitis C.
Feeney ER, Chung RT.
BMJ. 2014 Jul 7;349:g3308.
Abstract

Update on hepatitis C virus resistance to direct-acting antiviral agents.
Poveda E, Wyles DL, Mena A,  et al
Antiviral Res. 2014 Jun 6.
Abstract

FULL-TEXT ARTICLE
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
Xiao F, Fofana I, Thumann C, Mailly L, et al
Gut. 2014 May 21.
Paper

HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R, Halfon P, Marcellin P, Asselah T.
Liver Int
. 2014 Feb;34 Suppl 1:69-78.

Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries
Hill A, Khoo S, Fortunak J, et al

Clin Infect Dis. 2014 Jan 6.
Abstract

FULL-TEXT ARTICLE
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
Zhu Y, Chen S.
World J Gastroenterol. 2013 Dec 21;19(47):8963-8973.
Paper

Impact of Interferon Free Regimens on Clinical and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients.
Younossi ZM, Singer ME, Mir HM,  et al
J Hepatol
. 2013 Nov 19.
Abstract

Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.
Zhou H, Luo H, Xiao S,  et al
Eur J Clin Microbiol Infect Dis. 2013 Nov 6.
Abstract

Interferon-Free Regimens for Hepatitis C: Combine and Conquer.
Martel-Laferrière V, Bichoupan K, Dieterich DT.
BioDrugs
. 2013 Oct 30
.
Abstract

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C virus.
Maasoumy B, Port K, Calle Serrano B, et al
Aliment Pharmacol Ther. 2013 Oct 16
Abstract

Novel Therapeutic Approaches for Hepatitis C.
Au JS, Pockros PJ.
Clin Pharmacol Ther. 2013 Oct 14.
Abstract


Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
v
an der Meer AJ, Wedemeyer H, Feld JJ,  et al
J Hepatol
. 2013 Aug 20.
Abstract

Drug-drug interactions during antiviral therapy for chronic hepatitis C.
Kiser JJ, Burton JR Jr, Everson GT
Nat Rev Gastroenterol Hepatol. 2013 Jul 2.
Abstract

Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration.
Chan K, Lai MN, Groessl EJ,  et al
Clin Gastroenterol Hepatol
. 2013 May 22.
Abstract

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
Bruce RD, Moody DE, Altice FL,  et al
Expert Rev Clin Pharmacol
. 2013 May;6(3):249-69.
Abstract

Earlier Sustained Virologic Response Endpoints for Regulatory Approval and Dose Selection of Hepatitis C Therapies.
Chen J, Florian J, Carter W, Fleischer RD, et al
Gastroenterology
. 2013 Mar 4.
Abstract

FULL-TEXT ARTICLE
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 2012 • Boston, Massachusetts
[No authors listed]
Gastroenterol Hepatol (N Y)
. 2013 Jan;9(1 Suppl 1):1-20.
Paper

Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL, Locarnini S, Beard MR.
Antivir Ther. 2012;17(6 Pt B):1147-62.
Abstract

Future perspectives: towards interferon-free regimens for HCV.
Gane E.
Antivir Ther
. 2012;17(6 Pt B):1201-10.
Abstract

Highly active anti-hepatitis C therapy: seven lessons from HIV.
Thomas DL.
Antivir Ther
. 2012;17(6 Pt B):1183-8.
Abstract

HCV Variants with Decreased Sensitivity to Direct Acting Antivirals Were Rarely Observed in DAA-Naive Patients Prior to Treatment.
Bartels DJ, Sullivan JC, Zhang EZ, et al 
J Virol
. 2012 Nov 14.
Abstract

The changing face of hepatitis C in the new era of direct-acting antivirals.
Soriano V, Labarga P, Fernández-Montero JV,  et al
Antiviral Res
. 2012 Nov 9.
Abstract

FULL-TEXT PDF ARTICLE
New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA, Diotti RA, Clementi M.
New Microbiol. 2012 Oct;35(4):387-97.

Paper

Pharmacokinetics of new oral hepatitis C antiviral drugs.
Vispo E, Barreiro P, Soriano V.
Expert Opin Drug Metab Toxicol
. 2012 Oct 25.
Abstract

New hepatitis C virus drug discovery strategies and model systems.
Hussain S, Barretto N, Uprichard SL.
Expert Opin Drug Disc
ov
. 2012 Sep;7(9):849-59.
Abstract

aMximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS 4th, Fried MW
Gastroenterology. 2012 May;142(6):1314-1323.
Abstract

FULL-TEXT ARTICLE
New antiviral agents for hepatitis C.
Pawlotsky JM.
F1000 Biol Rep. 2012;4:5..
Paper

Antiviral Drugs and the Treatment of Hepatitis C.
Jalali Z, Rockstroh JK.
Curr HIV/AIDS Rep. 2012 Feb 22
Abstract

Antiviral strategies in hepatitis C virus infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.
J Hepatol
. 2012;56 Suppl:S88-S100
Abstract

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int
.2012 Feb;32 Suppl 1:88-102. .
Abstract

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P, Sarrazin C.
Liver Int. 2012 Feb;32 Suppl 1:79-87.
.
Abstract

New targets for antiviral therapy of chronic hepatitis C.
Bühler S, Bartenschlager R.
Liver Int. 2012 Feb;32 Suppl 1:9-16.
Abstract

FULL-TEXT ARTICLE
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
Gut Liver
. 2011 Dec;5(4):406-17
Paper

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C
in HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG, et al
Clin Infect Dis
. 2011 Dec 14
Abstract

Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2011 Nov;36(11):1025-36.
Abstract

Mechanisms Involved in the Development of Chronic Hepatitis C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M, Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol
. 2011 Sep 9.
Abstract

Oral combination therapy: Future hepatitis C virus treatment?
Hézode C.
J Hepatol
. 2011 May
Abstract

Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,  et al
J Pharm Pharmacol. 2011 Jul;63(7):883-92.
Abstract

Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Masarone M, Persico M.
Expert Rev Anti Infect Ther. 2011 May;9(5):535-43.
.
Abstract

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.
Pearlman BL, Traub N.
Clin Infect Dis. 2011 Apr;52(7):889-900
Abstract

Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C, Gadalean F, Kaycsa A, et al
Immunopharmacol Immunotoxicol
. 2011 Feb 14
Abstract

Hepatitis C virus Resistance to Protease Inhibitors.
Halfon P, Locarnini S.
J Hepatol
. 2011 Jan 29.
Abstract

Mixing the right hepatitis C inhibitor cocktail.
Gelman MA, Glenn JS.
Trends Mol Med
. 2010 Nov 22.
Abstract

Susceptibility of Treatment-Naive HCV Clinical Isolates to HCV Protease Inhibitors.
Bae A, Sun SC, Qi X, et al
Antimicrob Agents Chemother. 2010 Sep 20
Abstract

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,  et  al
Psychosomatics
. 2010 Sep;51(5):401-8.
Abstract

Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
Cooper C.
Can J Gastroenterol. 2010 Jun;24(6):385-90
Abstract

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S.
J Antimicrob Chemother
. 2010 Mar 23
Abstract


Atazanavir
 

    Conference Reports, Abstracts, and Posters
 
  Atazanavir and ritonavir pharmacokinetics with telaprevir-based HCV treatment (ANRSHC26)
A. Barrail-Tran, J. Braun, C. Vincent, et al
(XX International AIDS Conference)
Abstract

Daclatasvir
 

      Journal Papers, Abstracts, and Commentaries
 
  Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4).
Hézode C, Alric L, Brown A, Hassanein T,  et al
Antivir Ther. 2015 Aug 27.
Abstract

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
McPhee F, Suzuki Y, Toyota J, et al
Adv Ther. 2015 Jul 9
Abstract

Assessment of Drug-Drug Interactions Between Daclatasvir and Methadone or Buprenorphine/Naloxone.
Garimella T, Wang R, Luo WL,  et al
Antimicrob Agents Chemother
. 2015 Jun 29
Abstract

Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype 1 infection.
Kinugasa H, Ikeda F, Takaguchi K,  et al
Antivir Ther
. 2015 Jun 26
Abstract

Efficacy of Sofosbuvir and Daclatasvir in Patients with Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Leroy V, Dumortier J, Coilly A,  et al
Clin Gastroenterol Hepatol. 2015 Jun 1
Abstract

Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
Bunchorntavakul C, Reddy KR.
Aliment Pharmacol Ther. 2015 May 27
Abstract

Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Herzer K, Papadopoulos-Köhn A, Walker A,  et al
Digestion. 2015 May 19;91(4):326-333.
Abstract

High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced null-responder HIV/HCV genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.
Piroth L, Paniez H, Taburet AM,  et al
Clin Infect Dis
. 2015 May 14.
Abstract

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Muir AJ, Poordad F, Lalezari J, et al
JAMA
. 2015 May 5;313(17):1736-44
Abstract

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Poordad F, Sievert W, Mollison L, et al;
JAMA
. 2015 May 5;313(17):1728-35.
Abstract

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.
Garimella T, Wang R, Luo WL,  et al
Antivir Ther
. 2015 Feb 5.
Abstract

Daclatasvir: A Review of Its Use in Adult Patients with Chronic Hepatitis C Virus Infection.
McCormack PL.
Drugs
. 2015 Feb 27

Abstract

FULL-TEXT ARTICLE
A Randomized Trial of Daclatasvir in Combination With Asunaprevir and Beclabuvir in Patients With Chronic Hepatitis C Virus Genotype 4 Infection.
Hassanein T, Sims KD, Bennett M,  et al
J Hepat
ol. 2015 Jan 2. pii: S0168-8278(14)00954-4.
Paper

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V, Berger KL, Kelly SM,  et al
Virology. 2014 Dec 26;476C:168-179.
Abstract

In Vitro Activity and Resistance Profile of Dasabuvir, a Non-nucleoside HCV Polymerase Inhibitor.
Kati W, Koev G, Irvin M, et al
Antimicrob Agents Chemother
. 2014 Dec 22.
Abstract

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.
Friborg J, Zhou N, Han Z,
Infect Dis Ther
. 2014 Dec 17
Abstract

Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition.
Nettles JH, Stanton RA, Broyde J, et al
J Med Chem
. 2014 Nov 3
Abstract

Drug-Induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir.
Fujii Y, Uchida Y, Mochida S.
Hepatology
. 2014 Oct 12.
Abstract

Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection.
Dore GJ, Lawitz E, Hézode C,  et al
Gastroenterology. 2014 Oct 10
Abstract

Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
Aghemo A, De Francesco R.
Gut
. 2014 Sep 5.
Abstract

Daclatasvir + Asunaprevir: First Global Approval.
Poole RM.
Drugs. 2014 Aug 13

Abstract

The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus.
Eley T, Sevinsky H, Huang SP, et al
Clin Drug Investig
. 2014 Aug 13.

Abstract

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M, Pol S, Jacobson IM,  et al
Lancet
. 2014 Jul 26.
Abstract

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Hézode C, Hirschfield GM, Ghesquiere Wm et al
Gut
. 2014 Jul 30. pii: gutjnl-2014-307498.
Abstract

Efficacy of daclatasvir in hepatitis C virus.
Izumi N.
Expert Rev Anti Infect Ther
. 2014 Jul 25:1-7.

Abstract

Daclatasvir for the treatment of hepatitis C virus infection
Adler H, Lambert JS.
Expert Rev Gastroenterol Hepatol. 2014 May 31:1-14

Abstract

HCV Therapy With Daclatasvir, PEG-IFN, and RBV After Boceprevir-Based Therapy Failure Post-Liver Transplantation in Hyper-IgM Syndrome.
Reddy KR, Wirjosemito A, Pavri TM, Sinese L.
Transplantation
. 2014 Apr 27;97(8):e47-8
Abstract

Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect."
Belema M, Meanwell NA.
J Med Chem
. 2014 Apr 21
Abstract

FULL-TEXT ARTICLE
Daclatasvir plus sofosbuvir for HCV infection.
Sulkowski MS, Jacobson IM, Nelson DR.
N Engl J Me
d. 2014 Apr 17;370(16):1560-`1.
Paper

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Kumada H, Suzuki Y, Ikeda K et al
Hepatology. 2014 Mar 6.

Abstract

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection.
Everson GT, Sims KD, Rodriguez-Torres M,  et al
Gastroenterology
. 2014 Feb;146(2):420-9.
Abstract

Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients treated with daclatasvir, peg-interferon and ribavirin.
Murakami E, Imamura M, Hayes CN, et al
Antimicrob Agents Chemothe
r
. 2014 Jan 27
Abstract

Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F, Hernandez D, Zhou N,  et al
Antivir Ther. 2014 Jan 22.
Abstract

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Suzuki F, Toyota J, Ikeda K,  et al
Antivir Ther
. 2014 Jan 22.
Abstract

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M,  et al
N Engl J Med
. 2014 Jan 16;370(3):211
Abstract

Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A.
Gentile I, Borgia F, Coppola N, et al
Curr Med Chem
. 2013 Dec 28.
Abstract

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
Bifano M, Sevinsky H, Hwang C,  et al
Antivir Ther
. 2013 Dec 17
Abstract

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection.
Everson GT, Sims KD, Rodriguez-Torres M,  et al
Gastroenterology
. 2013 Oct 30.
Abstract

Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.
Ke R, Loverdo C, Qi H,  et al
J Antimicrob Chemother
. 2013 Oct 29
Abstract

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
O'Boyle DR 2nd, Nower PT, Sun JH, et al
J Virol Methods. 2013 Oct;193(1):68-76

Abstract

FULL-TEXT ARTICLE

Daclatasvir: potential role in hepatitis C.
Lee C.
Drug Des Devel Ther
. 2013 Oct 16;7:1223-33
Paper

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M, Hwang C, Oosterhuis B,
Antivir Ther. 2013 Aug 20

Abstract

Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus
Aghemo A, Colombo M.
Gastroenterology. 2013 Jul;145(1):247-9

Abstract

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.
Guedj J, Dahari H, Uprichard SL, Perelson AS.
Expert Rev Gastroenterol Hepatol
. 2013 Jul;7(5):397-9
Abstract

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M,  et al
Am J Transplant
. 2013 Jun;13(6):1601-5.
Abstract

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Suzuki Y, Ikeda K, Suzuki F,  et al
J Hepatol
. 2013 Apr;58(4):655-62.
Abstract

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F,  et al
Hepatology. 2013 Mar 15.
Abstract

FULL-TEXT ARTICLE
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Guedj J, Dahari H, Rong L,  et al
Proc Natl Acad Sci U S A
. 2013 Mar 5;110(10):3991-6.
Paper

   Videos

A New Way to HIV Functional Cure: HIV Pathogenesis Sabotage with Dolutegravir

Dasabuvir (ABT 333)
 

      Journal Papers, Abstracts, and Commentaries
 
  Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Trivella JP, Gutierrez J, Martin P.
Expert Opin Pharmacother. 2015 Mar;16(4):617-24.
Abstract

In Vitro Activity and Resistance Profile of Dasabuvir, a Non-nucleoside HCV Polymerase Inhibitor.
Kati W, Koev G, Irvin M,  et al
Antimicrob Agents Chemother
. 2014 Dec 22. pii: AAC.04619-14.
Abstract

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection.
Gentile I, Buonomo AR, Borgia G.
Rev Recent Clin Trials
. 2014 May 29.

Abstract

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, et al
N Engl J Med. 2014 May 22;370(21):1983-92.
Abstract


Erythropoietin
 

     Journal Papers, Abstracts, and Commentaries
 
 

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
Sherman M, Cohen L, Cooper MA, et al 
Can J Gastroenterol.
2006 Jul;20(7):479-85.

Abstract

Epoetin alfa for the Treatment of Combination Therapy-Induced Hemolytic Anemia in Patients Infected with Hepatitis C Virus.
Rivkin AM, Chawla S. 
Pharmacotherapy. 2005 Jun;25(6):862-7
Abstract 

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Durante Mangoni E, Marrone A, Saviano D
Antivir Ther. 2003 Feb;8(1):57-63
Abstract

Ledipasvir
HIV/HCV Indications

     Internet Document
 
  FULL-TEXT DOCUMENT
Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
2015  Jan 16.

Guidelines

      Journal Papers, Abstracts, and Commentaries
 

 

Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
Stedman CA, Hyland RH, Ding X,
Haemophilia. 2015 Aug 28.
Abstract

Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection.
Gane EJ, Hyland RH, An D,  et al
Gastroenterology. 2015 Aug 7
Abstract

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
Kohli A, Kapoor R, Sims Z, et al
Lancet Infect Dis
. 2015 Jul 14.
Abstract

The Impact of Ledipasvir/Sofosbuvir on Patient-Reported Outcomes in Cirrhotic Patients with Chronic Hepatitis C: The SIRIUS Study.
Younossi ZM, Stepanova M, Pol S,  et al
Liver Int
. 2015 Jun 9.
Abstract

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
Alqahtani SA, Afdhal N, Zeuzem S,  et al
Hepatology
. 2015 May 11.

Abstract

FULL-TEXT ARTICLE
Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent.
Kwon HJ, Xing W, Chan K, et al 
PLoS One. 2015 Apr 9;10(4):e0122844.
Paper

Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C.
Keating GM.
Drugs. 2015 Apr 3.
Abstract

Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States.
Chhatwal J, Kanwal F, Roberts MS, Dunn MA.
Ann Intern Med
. 2015 Mar 17;162(6):397-406
Abstract

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M, Bronowicki JP, de Ledinghen V, et al
Lancet Infect Dis. 2015 Mar 12. pii: S1473-3099(15)70050-2.
Abstract

Ledipasvir/sofosbuvir regimens for chronic hepatits c (chc) infection: insights from a work productivity economic model from the United States.
Younossi Z, Jiang Y, Smith NJ,  et al
Hepatology. 2015 Feb 23
Abstract

Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the Ion-1, 2 and 3 clinical trials
Younossi ZM, Stepanova M, Marcellin P,  et al
Hepatology
.
2015 Jan 27.
Abstract

Ledipasvir-Sofosbuvir: Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection.
Smith MA, Chan J, Mohammad RA.
Ann Pharmacother. 2014 Dec 16.
Abstract

Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse: An Open-Label Pilot Study.
Osinusi A, Kohli A, Marti MM, et al
Ann Intern Med
. 2014 Nov 4;161(9):634-8.

Abstract

Lack of a Clinically Important Pharmacokinetic Interaction Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects.
German P, Moorehead L, Pang PS, et al
J Clin Pharmacol
. 2014 Jun 13
Abstract

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet. 2013 Nov 1.
Abstract

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection.
Afdhal N, Zeuzem S, Kwo P,  et al
N Engl J Med. 2014 Apr 11.
Abstract

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.
Gentile I, Buonomo AR, Borgia F,  et al 
Expert Opin Investig Drugs
. 2014 Mar 4
Abstract

All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection.
Wyles DL, Rodriguez-Torres M, Lawitz E, , et al
Hepatology. 2014 Feb 5.

Abstract

The Discovery of Ledipasvir (GS-5885), a Potent Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection.
Link JO, Taylor JG, Xu L,  et al 
J Med Chem. 2013 Dec 9

Abstract


Mericitabine
 

      Journal Papers, Abstracts, and Commentaries
 
  In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis
. 2013 Nov 11
Abstract

Nevirapine
 

     Journal Papers, Abstracts, and Commentaries
 
  Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens : CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
Torti C, Costarelli S, De Silvestri A, et al 
Drug Saf.
2007;30(12):1161-9.

Abstract

Ombitasvir
Viekira Pak

 
    Journal Papers, Abstracts, and Commentaries
 
  Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir.
Schnell G, Tripathi R, Beyer J, et al 
Antimicrob Agents Chemother
. 2015 Aug 17.
Abstract

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
Kumada H, Chayama K, Rodrigues-Jr L,  et al
Hepatology. 2015 Jul 3
Abstract

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED.
Drugs
. 2015 Jun;75(9):1027-38.
Abstract

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
Hézode C, Asselah T, Reddy KR, et al
Lancet
. 2015 Mar 30.
Abstract

Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hcv-infected patients
Chayama K, Notsumata K, Kurosaki M,  et al
Hepatology
. 2015 Jan 16.
Abstract

Exploratory Trial of Ombitasvir and ABT-450/r With or Without Ribavirin for HCV Genotype 1, 2, and 3 Infection.
Lawitz E, Sullivan G, Rodriguez-Torres M,  et al
J Infect. 2014 Sep 19. pii: S0163-4453(14)00287-4.
Abstract

Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.
Gentile I, Buonomo AR, Borgia G.
Expert Rev Anti Infect Ther. 2014 Jul 30:1-11
Abstract

ABT-450: A Novel Protease Inhibitor For the Treatment of Hepatitis C Virus Infection.
Gentile I, Borgia F, Buonomo AR, et al
Curr Med Chem
. 2014 Jul 6
Abstract

FULL-TEXT ARTICLE
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, et al
N Engl J Med
. 2014 May 4
Paper

ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis.
Poordad F, Hezode C, Trinh R, et al
N Engl J Med. 2014 Apr 11

Abstract

Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin.
Feld JJ, Kowdley KV, Coakley E, et al
N Engl J Med
. 2014 Apr 10.
Abstract

Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin.
Zeuzem S, Jacobson IM, Baykal T, et al
N Engl J Med. 2014 Apr 10.
Abstract


Paritaprevir (ABT-450)
Viekira Pak

     Journal Papers, Abstracts, and Commentaries
 
  Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
Khatri A, Menon R, Marbury TC, et al
J Hepatol. 2015 Jun 9.
Abstract

ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Gamal N, Vitale G, Andreone P.
Expert Rev Anti Infect Ther. 2015 Jan 12:1-10
Abstract

An interferon-free antiviral regimen for HCV after liver transplantation.
Kwo PY, Mantry PS, Coakley E,  et al
N Engl J Med. 2014 Dec 18;371(25):2375-82.
Abstract

ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
Gentile I, Borgia F, Buonomo AR,  et al
Curr Med Chem. 2014;21(28):3261-70.
Abstract

New antiviral agents for the treatment of hepatitis C: ABT-450.
Carrion AF, Gutierrez J, Martin P.
Expert Opin Pharmacother. 2014 Apr;15(5):711-6.
Abstract

FULL-TEXT ARTICLE
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Kowdley KV, Lawitz E, Poordad F,  et al
Engl J Med. 2014 Jan 16;370(3):222-32
Paper


Raltegravir
 

     Journal Papers, Abstracts, and Commentaries
 
 

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment.
Ehret R, Walter H, Ingiliz P, et al
J Int AIDS Soc
. 2014 Nov 2;17(4 Suppl 3):1964
Abstract

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother
. 2009 Dec 23

Abstract


Rifampin
 

Rifampin/Pyrazinamide

     Journal Papers, Abstracts, and Commentaries

  Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D, Warman A, Beckon A,  et al.
Clin Infect Dis. 2003 Jun 15;36(12):E158-61

Abstract
 
Rituximab
 

   Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.
Bonilla-Abadía F, Echeverri AF,  et al
Case Report Rheumatol. 2012;2012:923897.
Paper

FULL-TEXT ARTICLE
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.
Stamataki Z, Tilakaratne S, Adams DH, McKeating JA.

PLoS One
. 2011;6(9):e25789.
Paper

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood
. 2010 May
Abstract

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup
study of thirty-two patients.
Terrier B, Saadoun D, Sène D, et al
Arthritis Rheum
. 2009 Jul 30;60(8):2531-2540.
Abstract

Hepatitis C virus infection and rituximab therapy after renal transplantation.
Fabrizi F, Martin P, Elli A, et al 
Int J Artif Organs.
2007 May;30(5):445-9.

Abstract


Sofosbuvir
 

      News Releases
 
  U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Gilead
Dec. 6, 2013
News
 
     Internet Books and Documents
 
  iNTERNET DOCUMENT
Triple Therapy for Hepatitis C in Previous Non-responders: A Review of the Clinical Effectiveness and Safety
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
2014 Dec 08.
.
Document

INTERNET BOOK
Sofosbuvir (Sovaldi): Sofosbuvir is Indicated for the Treatment of Chronic Hepatitis C Virus (CHC) Infection in Adult Patients With Compensated Liver Disease,
Including Cirrhosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
2014 Oct
.
Book

      Journal Papers, Abstracts, and Commentaries
 

 
FULL-TEXT ARTICLE
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
Do A, Mittal Y, Liapakis A,  et al
PLoS One
. 2015 Aug 27;10(8):e0135645.
Paper

Development of sofosbuvir for the treatment of hepatitis C virus infection.
Lawitz E, Jacobson IM, Nelson DR, et al
Ann N Y Acad Sci
. 2015 Jul 31.
Abstract

Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin: A Matched Analysis
Saab S, Jimenez M, Bau S,  et al
Clin Transplant. 2015 Jul 4.
Abstract

Temporal dynamics of inflammatory cytokines/chemokines during Sofosbuvir and Ribavirin therapy for Genotype 2 and 3 Hepatitis C infection.
Carlin AF, Aristizabal P, Song Q, et al
Hepatology. 2015 Jul 3
Abstract

'Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Barua S, Greenwald R, Grebely J, et al
Ann Intern Med
. 2015 Jun 30
Abstract

Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.
Cortesi PA, Mantovani LG, Ciaccio A, et al
Am J Transplant
. 2015 Jul;15(7):1817-26
Abstract

A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis.
Perumpail RB, Wong RJ, Pham EA, et al 
Dig Dis Sci. 2015 Jun 17.
Abstract

Efficacy of Sofosbuvir and Daclatasvir in Patients with Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Leroy V, Dumortier J, Coilly A,  et al
Clin Gastroenterol Hepatol. 2015 Jun 1
Abstract

FULL-TEXT ARTICLE
Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir.
Ascha M, Ascha M, Zein NN,
Int J Organ Transplant Med
. 2015;6(2):86-90.
Paper

Sofosbuvir Plus Ribavirin for Treating Egyptian Patients With Hepatitis C Genotype 4.
Doss W, Shiha G, Hassany M,  et al
Hepatol. 2015 Apr 30
Abstract

FULL-TEXT ARTICLE
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Vionnet J, Pascual M, Chtioui H,
BMC Gastroenterol. 2015 Mar 26;15(1):38.
Paper

Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States.
Chhatwal J, Kanwal F, Roberts MS, Dunn MA.
Ann Intern Med
. 2015 Mar 17;162(6):397-406
Abstract

Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
Floreani A.
Expert Opin Pharmacother
. 2015 Mar 1:1-4
Abstract

Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
Kumari R, Nguyen MH.
Expert Opin Pharmacother. 2015 Feb 13:1-10
Abstract

FULL-TEXT ARTICLE
Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection.
Waheed Y.
World J Virol
. 2015 Feb 12;4(1):33-5.
Paper

Optimal duration to pre-liver transplantation anti-hepatitis C treatment with direct-acting agent Sofosbuvir.
Donato MF, Malinverno F, Monico S.
Liver Int
. 2015 Feb 11.

Abstract

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM, Orkin C, Iser DM, et al
Lancet. 2015 Feb 3. pii: S0140-6736(14)62483-1
Abstract

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
D'Ambrosio R, Aghemo A, Colombo M.
Expert Opin Drug Saf
. 2015 Feb 3:1-12.

Abstract

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.
Patel N, Nasiri M, Koroglu A, et al
Infect Dis Ther
. 2015 Jan 28.
Abstract

Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete
[No authors listed]
Prescrire Int. 2015 Jan;24(156):5-10.
Abstract

Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection.
Childs-Kean LM, Hand EO.
Clin Ther. 2015 Jan 16. pii: S0149-2918(14)00870-4
Abstract

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation.
Forns X, Charlton M, Denning J,  et al
Hepatology
. 2014 Dec 29.
Abstract

The Combination of Simeprevir and Sofosbuvir is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients with Hepatitis C-related Child's Class A Cirrhosis.
Pearlman BL, Ehleben C, Perrys M.
Gastroenterology
. 2014 Dec 31. pii: S0016-5085(14)01579-0.
Abstract

Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in US. Incarcerated populations: a cost-effectiveness analysis.
Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD.
Ann Intern Med. 2014 Oct 21;161(8):546-53.
Abstract

FULL-TEXT ARTICLE
Sofosbuvir: A novel treatment option for chronic hepatitis C infection.
Bhatia HK, Singh H, Grewal N, Natt NK.
J Pharmacol Pharmacother
. 2014 Oct;5(4):278-284.

Paper

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E, Poordad F, Brainard DM, et al 
Hepatology. 2014 Oct 16
Abstract

Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus.
Yoshida EM, Sulkowski MS, Gane EJ,  et al
Hepatology
. 2014 Oct 14
Abstract

FULL-TEXT ARTICLE
Sofosbuvir: A novel treatment option for chronic hepatitis C infection.
Bhatia HK, Singh H, Grewal N, Natt NK.
J Pharmacol Pharmacother. 2014 Oct;5(4):278-284.
Paper

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation.
Charlton M, Gane E, Manns MP, et al
Gastroenterology
. 2014 Oct 7.
Abstract

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study.
Curry MP, Forns X, Chung RT, Terrault NA, et al.
Gastroenterology. 2014 Sep 24
Abstract

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients.
Meissner EG, Lee YJ, Osinusi A,  et al
Hepatology
. 2014 Sep 9
Abstract

 

CON Sofosbuvir and Ribavirin Use in Wait-Listed Patients with Hepatitis C Should be Selective.
Price JC, Terrault NA.
Liver Int. 2014 Sep 2.
Abstract

Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
Summers BB, Beavers JW, Klibanov OM.

J Pharm Pharmacol
. 2014 Aug 31.

Abstract

Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient.
Borentain P, Colson P, Dhiver C,  et al
Antivir Ther. 2014 Aug 8.
Abstract

FULL-TEXT ARTICLE
Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.
Peixoto RD, Renouf DJ, Gill S,  et al J
Gastrointest Oncol
. 2014 Aug;5(4):259-64
Paper

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S, Gordon SC, Park H,  et al
Aliment Pharmacol Ther
. 2014 Jul 28
Abstract

Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
Gentile I, Borgia G.
Evid Based Med. 2014 Jul 15.
Abstract

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late.
Pellicelli AM, Montalbano M, Lionetti R, et al
Dig Liver Dis. 2014 Jul 2.
Abstract

Sofosbuvir for the treatment of chronic hepatitis C virus infection.
Temesgen Z, Talwani R, Rizza SA.
Drugs Today (Barc). 2014 Jun;50(6):421-434.|
Abstract

Lack of a Clinically Important Pharmacokinetic Interaction Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects.
German P, Moorehead L, Pang PS, et al
J Clin Pharmacol
. 2014 Jun 13
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.
Rose L, Bias TE, Mathias CB,  et al
Ann Pharmacother. 2014 May 8
Abstract

FULL-TEXT ARTICLE
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential.

Stedman C.
Therap Adv Gastroenterol
. 2014 May;7(3):131-140.
Paper

FULL-TEXT ARTICLE
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3.
Zeuzem S, Dusheiko GM, Salupere R, et sl
N Engl J Med. 2014 May 4.
Paper

Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
Sofia MJ.
Antiviral Res. 2014 May 2.
Abstract

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives.
Degasperi E, Aghemo A.

Hepat Med
. 2014 Apr 29;6:25-33
Abstract

Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks.
Abraham GM, Spooner LM.
Clin Infect Dis. 2014 Apr 18
Abstract

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection.
Afdhal N, Zeuzem S, Kwo P,  et al
N Engl J Med
. 2014 Apr 11.
Abstract

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection.
Afdhal N, Reddy KR, Nelson DR,  et al
N Engl J Med. 2014 Apr 11
Abstract

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM, Stepanova M, Nader F,  et al
Hepatology. 2014 Apr 8.
Abstract

FULL-TEXT PDF ARTICLE
[MUST BE DOWNLOADED DIRECTLY FROM SITE)

Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
Gaetano JN.
Drug Healthc Patient Saf. 2014 Mar 31;
Paper

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals.
Hagan LM, Sulkowski MS, Schinazi RF.
Hepatology
. 2014 Mar 28.
Abstract

Hepatitis C virus: Here comes all-oral treatment.
Dugum M, O'Shea R.
Cleve Clin J Med
. 2014 Mar;81(3):159-72.
Abstract

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors
Mericitabine and Sofosbuvir.

Tong X, Le Pogam S, Li L, et al
J Infect Dis. 2014 Mar;209(5):668-75.

Abstract

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Koff RS.
Aliment Pharmacol Ther
. 2014 Mar;39(5):478-87
Abstract

Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Guedj J, Pang PS, Denning J, Rodriguez-Torres M,  et al
Antivir Ther
. 2014 Jan 24.

Abstract

Sofosbuvir for the treatment of hepatitis C virus.
Asselah T.
Expert Opin Pharmacother
. 2014 Jan;15
Abstract

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
Koff RS.
Aliment Pharmacol Ther
. 2014 Jan 6.

Abstract

IFNL4-ΔG Genotype is Associated with Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated with Sofosbuvir and Ribavirin.
Meissner EG, Bon D, Prokunina-Olsson L,  et al
J Infect Dis. 2013 Dec 23.

Abstract

FULL-TEXT ARTICLE

Sofosbuvir has come out of the magic box.
Alavian SM.
Hepat Mon. 2013
16;13(12):e16916.
Paper


Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics.
Ferguson MC.
Evid Based Med
. 2013 Dec 12.
Abstract

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther
. 2013 Dec;11(12):1269-79.
Abstract

Effects of Sofosbuvir-based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C.
Younossi ZM, Stepanova M, Henry L,  et al
Clin Gastroenterol Hepatol
. 2013 Dec 5.
Abstract

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther
. 2013 Dec;11(12):1269-79.
Abstract

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection.
Gane EJ, Stedman CA, Hyland RH, et al
Gastroenterology
. 2013 Nov 18.
Abstract

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis
. 2013 Nov 11
Abstract

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet. 2013 Nov 1.

Abstract

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F,  et al
Hepatology
. 2013 Sep;58(3):902-11
Abstract

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Osinusi A, Meissner EG, Lee YJ,  et al
JAMA
. 2013 Aug 28;310(8):804-11
Abstract

FULL-TEXT ARTICLE
Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Zeng QL, Zhang JY, Zhang Z, et al
World J Gastroenterol
. 2013 Jun 7;19(21):3199-206
Paper

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M, et al
Am J Transplant
. 2013 Jun;13(6
Abstract

Sofosbuvir-Based Antiviral Therapy for Treatment Naïve Hepatitis C Genotypes 1, 2, and 3.
Sharma P.
Gastroenterology
. 2013 May 27.
Abstract

FULL-TEXT ARTICLE
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C, Sun JH, O'Boyle DR 2nd, et aL
Antimicrob Agents Chemother. 2013 May;57(5):2054-65
Paper

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection:
a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T,  et al
Lancet Infect Dis
. 2013 May;13(5):401-8.
Abstract

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M,  et al
N Engl J Med. 2013 Apr 23.
Abstract

FULL-TEXT ARTICLE
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Herbst DA Jr, Reddy KR.
Expert Opin Investig Drugs
. 2013 Apr;22(4):527-36.
Abstract
 

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.
Jacobson IM, Gordon SC, Kowdley KV,  et al
N Engl J Med
. 2013 Apr 23.
Abstract

Sofosbuvir , a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Herbst DA Jr, Reddy KR.
Expert Opin Investig Drugs
. 2013 Mar 1.

Abstract

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised,
multicentre phase 2 trial.
Kowdley KV, Lawitz E, Crespo I,  et al
Lancet. 2013 Mar 14
Abstract

   
 

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Gane EJ, Stedman CA, Hyland RH,
N Engl J Med
. 2013 Jan 3;368(1):34-44.
Abstract

  Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M, Lawitz E,  et a;
J Hepatol. 2012 Nov 23.

Abstract
   
 

FULL-TEXT ARTICLE
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.
Lam AM, Espiritu C, Bansal S, Micolochick S
Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68
Paper

 

Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
Chun BK, Du J, Zhang HR,
Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):886-96
Abstract

 

Statins
 

   Journal Papers, Abstracts, and Commentaries
 
  Are statins a viable option for the treatment of infections with the hepatitis C virus?
Verpaalen B, Neyts J, Delang L.
Antiviral Res
. 2014 Mar 5.
.
Abstract

Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans.
Henderson LM, Patel S, Giordano TP, et al 
Dig Dis Sci
. 2009 Sep 3.
Abstract


Steroid Therapy
 

 Journal Papers, Abstracts, and Commentaries
 
  Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?
Romero Gutiérrez M, Del Campo Terrón S,  et al
J Med Virol
. 2014 May;86(5):758-64.

Abstract
   

Viekira Pak/Holkira (Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir)
 

  News
 
 

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
PRNewswire Dec. 19, 2014
News Release

     Internet Document
 
  FULL-TEXT DOCUMENT
Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
2015  Jan 16.
Guidelines

Journal Papers, Abstracts, and Commentaries
 

  Randomized trials of ombitasvir/paritaprevir/r+dasabuvir±ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV.
Dore GJ, Conway B, Luo Y, et al  
J Hepatol
. 2015 Aug 27.
Abstract

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED.
Drugs. 2015 Jun;75(9):1027-38.
Abstract

Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine.
Lalezari J, Sullivan JG, Varunok P, et al

J Hepatol
. 2015 Mar 31
Abstract

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection.
Klibanov OM, Gale SE, Santevecchi B.
Ann Pharmacother
. 2015 Feb 13.

Abstract

Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir.
Menon R, Badri P, Wang T, et al
J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00057-4
Abstract

Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study.
Poordad F, Agarwal K, Younes Z,
Clin Infect Dis
. 2014 Nov 2. pii: ciu865.
Abstract

FULL-TEXT ARTICLE
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P, Colombo MG, Enejosa JV, et al
Gastroenterology
. 2014 Aug;147(2):359-365.e1.
Paper

FULL-TEXT ARTICLE
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J,  et al
N Engl J Med
. 2014 May 22;370(21):1983-92
Paper

FULL-TEXT ARTICLE
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Poordad F, Hezode C, Trinh R,  et al
N Engl J Med
. 2014 May 22;370(21):1973-82
Paper

FULL-TEXT ARTICLE
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Feld JJ, Kowdley KV, Coakley E, et al
N Engl J Med
. 2014 Apr 24;370(17):1594-603.
Paper

FULL-TEXT ARTICLE
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Zeuzem S, Jacobson IM, Baykal T,  et al
N Engl J Med. 2014 Apr 24;370(17):1604-14.
Paper

ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.
Asselah T.
J Hepatol
. 2013 Oct;59(4):885-8.
Abstract

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Lawitz E, Poordad F, Kowdley KV, et al
J Hepatol
. 2013 Jul;59(1):18-23.
Abstract

    Conference Reports, Abstracts, and Posters

  TURQUOISE-I: safety and efficacy of ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin in patients co-infected with hepatitis C and HIV-1
M. Sulkowski, J.J. Eron, D. Wyles, et al
(
XX International AIDS Conference)
Abstract

SAPPHIRE-I subpopulation analysis: ABT-450/r/ABT-267, ABT-333, and ribavirin regimen achieves high sustained virologic response rates 12 weeks post-treatment in treatment-naïve patients with chronic HCV GT 1 infection, regardless of baseline characteristics
S. Shafran, S. Roberts, D. Crawford, et al
(
XX International AIDS Conference)
Abstract

SAPPHIRE-II subgroup analysis: ABT-450/r/ABT-267, ABT-333, and ribavirin regimen achieves high sustained virologic response rates 12 weeks post-treatment in treatment-experienced patients with chronic HCV GT 1 infection, regardless of baseline characteristics
S.I. Strasser, K. Agarwal, M. Diago, et al
(
XX International AIDS Conference)
Abstract


Alternate Therapies
 

     Journal Papers, Abstracts, and Commentaries

 
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Biermer M, Schlosser B, Fülöp B, et al

J Viral Hepat
. 2012 Aug;19(8):547-53
Abstract

High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure
Estes JD, Stolpman D, Olyaei A 

Arch Surg.
2003 Aug;138(8):852-8.
Abstract

 

 

HCV Main Page Main New/Newsworthy    Home Page    

HCV Drugs